Determining the Minimal Clinically Important Difference of the Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire to Evaluate the Change in the Quality of Life of Patients With Pancreatic Cancer During Radiation Therapy
Isabella Zaniletti, T.A. DeWees(Mayo Clinic in Arizona), Byron C. May(Naval Medical Center San Diego), Todd R. Leavitt(Cytel (United States)), Christopher L. Hallemeier(Mayo Clinic in Arizona), Michael G. Haddock(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Jonathan B. Ashman(Mayo Clinic in Arizona), James L. Leenstra(WinnMed), Heather Gunn(University of California, Los Angeles), Brady S. Laughlin(Mayo Clinic in Florida)
International Journal of Radiation Oncology*Biology*Physics
August 14, 2023
Cited by 1
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
|Journal of Clinical Oncology|2008|270
Oesophageal cancer
|The Lancet|2024|265